Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects

被引：0
作者：
Fanny Monneaux
Sylviane Muller
机构：
[1] Institut de Biologie Moléculaire et Cellulaire,CNRS, Immunologie et Chimie Thérapeutiques
来源：
Arthritis Research & Therapy | / 11卷
关键词：
Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Patient; Bortezomib; Lupus Nephritis; Bromocriptine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this review article is to highlight emerging pharmacological options and new therapeutic avenues for lupus with a particular focus on non-antibody molecular strategies.
引用
收藏
相关论文
共 365 条
[1]  
Kaul A(2006)New therapies for systemic lupus erythematosus: has the future arrived? Future Rheumatol 1 235-247
[2]  
D'Cruz D(2007)T-cell therapies: lessons learned and future prospects Nat Immunol 8 T25-30
[3]  
Hughes GRV(2007)Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial Arthritis Rheum 56 4142-4150
[4]  
Liu EH(1990)Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses Clin Exp Immunol 81 446-453
[5]  
Siegel RM(2005)Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus Ann Rheum Dis 64 1517-1519
[6]  
Harlan DM(1995)FK506 therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice Arch Dermatol Res 287 558-563
[7]  
O'Shea JJ(2008)Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation Eur J Clin Pharmacol 64 337-341
[8]  
Dall'era M(2006)Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus Arthritis Rheum 54 2983-2988
[9]  
Chakravarty E(2004)Human lupus T cells resist inactivation and escape death by up-regulating COX-2 Nat Med 10 411-415
[10]  
Wallace D(2002)Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE Lupus 11 340-347
12345678910